Cai Ming, Ni Wei-Jian, Wang Ying-Hong, Wang Jing-Ji, Zhou Hong
Department of Pharmacy, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Anhui Acupuncture and Moxibustion Clinical Medicine Research Center, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
Front Oncol. 2022 Jun 6;12:906372. doi: 10.3389/fonc.2022.906372. eCollection 2022.
According to authoritative surveys, the overall morbidity and mortality of malignant tumors show an upward trend, and it is predicted that this trend will not be well contained in the upcoming new period. Since the influencing factors, pathogenesis, and progression characteristics of malignant tumors have not been fully elucidated, the existing treatment strategies, mainly including surgical resection, ablation therapy and chemotherapy, cannot achieve satisfactory results. Therefore, exploring potential therapeutic targets and clarifying their functions and mechanisms in continuous research and practice will provide new ideas and possibilities for the treatment of malignant tumors. Recently, a double-transmembrane protein named transmembrane protein 88 (TMEM88) was reported to regulate changes in downstream effectors by mediating different signaling pathways and was confirmed to be widely involved in cell proliferation, differentiation, apoptosis and tumor progression. At present, abnormal changes in TMEM88 have been found in breast cancer, ovarian cancer, lung cancer, thyroid cancer and other malignant tumors, which has also attracted the attention of tumor research and attempted to clarify its function and mechanism. However, due to the lack of systematic generalization, comprehensive and detailed research results have not been comprehensively summarized. In view of this, this article will describe in detail the changes in TMEM88 in the occurrence and development of malignant tumors, comprehensively summarize the corresponding molecular mechanisms, and explore the potential of targeting TMEM88 in the treatment of malignant tumors to provide valuable candidate targets and promising intervention strategies for the diagnosis and cure of malignant tumors.
据权威调查显示，恶性肿瘤的总体发病率和死亡率呈上升趋势，预计在未来一段时间内这一趋势仍难以得到有效遏制。由于恶性肿瘤的影响因素、发病机制及进展特征尚未完全阐明，现有的治疗策略，主要包括手术切除、消融治疗及化疗，均无法取得令人满意的效果。因此，在持续的研究与实践中探索潜在的治疗靶点并阐明其功能及机制，将为恶性肿瘤的治疗提供新的思路与可能。最近，一种名为跨膜蛋白88（TMEM88）的双跨膜蛋白被报道可通过介导不同信号通路调节下游效应分子的变化，并被证实广泛参与细胞增殖、分化、凋亡及肿瘤进展。目前，在乳腺癌、卵巢癌、肺癌、甲状腺癌等多种恶性肿瘤中均发现了TMEM88的异常变化，这也引起了肿瘤研究领域的关注，并试图阐明其功能及机制。然而，由于缺乏系统的归纳总结，尚未对全面而详细的研究成果进行综合概括。鉴于此，本文将详细阐述TMEM88在恶性肿瘤发生发展过程中的变化，全面总结其相应的分子机制，并探讨靶向TMEM88在恶性肿瘤治疗中的潜力，为恶性肿瘤的诊断与治愈提供有价值的候选靶点及有前景的干预策略。
